Browsing Tag
Avacta Therapeutics
9 posts
Avacta Therapeutics (AIM: AVCT) names Richard Hughes chairman as Shaun Chilton steps back
Avacta hands the chair to dealmaker Richard Hughes and adds a biotech deputy, a boardroom rebuild aimed squarely at pharma partnering. Read more.
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
Avacta Group (AIM: AVCT) delivers preCISION payload data that challenges Enhertu and Datroway tumor selectivity at Science Day 2026
Avacta is no longer pitching a platform. It is benchmarking preCISION directly against Enhertu and Datroway, and the tumor selectivity numbers matter.
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
Avacta Therapeutics (AIM: AVCT) elevates Francis Wilson to CSO as faridoxorubicin dosing cap is removed
Avacta Therapeutics lifts AVA6000 dosing cap and appoints a new Chief Scientific Officer. Explore what this means for pre|CISION and investors.
Avacta Therapeutics (AIM: AVCT) secures FDA clearance for AVA6103 as pre|CISION platform enters its second clinical test
Avacta Therapeutics secures FDA IND clearance for AVA6103, advancing its pre|CISION platform into a second clinical program. Read what changes next.
Avacta Therapeutics (AIM: AVCT) reports 90% disease control rate in faridoxorubicin salivary gland cancer trial
Avacta Therapeutics’ AVA6000 trial shows a 90% disease control rate in salivary gland cancer. Find out how its tumor-activated approach could reshape chemotherapy.
Is Avacta Therapeutics changing the rules of chemotherapy? Inside the Phase 1a findings that impressed ESMO
Avacta Therapeutics’ Phase 1a trial data shows faridoxorubicin’s tumor-targeted action and cardiac safety. Explore the implications for pre|CISION in solid tumors.